STOCK TITAN

ORTHOPEDIATRICS (KIDS) SEC Filings

KIDS NASDAQ

OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.

The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.

Rhea-AI Summary

OrthoPediatrics Corp. (KIDS) reported third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier; nine-month revenue was $202.5 million, up 16% from $174.7 million. Management attributed growth primarily to global trauma and deformity products and specialty bracing. Gross margin was 74% in the quarter, unchanged year over year, and 74% for nine months, versus 73% in 2025. Net loss was $5.9 million for the quarter and $23.8 million for nine months, compared with $11.8 million and $29.5 million, respectively.

For the nine months ended September 30, 2026, net cash provided by operating activities was $2.1 million, compared with $15.2 million used in the prior-year period. Cash and cash equivalents, restricted cash and short-term investments totaled $44.9 million at September 30, 2026, while accumulated deficit was $299.0 million. Management believes available liquidity and expected operating cash flows are sufficient to maintain current and essential planned operations for more than the next twelve months.

A March 2026 amendment established a delayed draw term loan facility of not more than $20.0 million, subject to conditions, that may be drawn until June 30, 2027, in minimum $10.0 million increments. No amounts had been drawn as of September 30, 2026; loans are interest-only until August 5, 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.30%
Tags
quarterly report
-
Rhea-AI Summary

OrthoPediatrics Corp. (KIDS) furnished its October 2026 investor presentation for use in upcoming presentations to investors and analysts. It reports third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. Gross profit was $54.0 million; operating loss was $4.2 million versus $9.4 million, and net loss was $5.9 million versus $11.8 million. Diluted loss per share was $0.25 versus $0.50. Adjusted EBITDA, a non-GAAP measure, was $6.9 million versus $6.2 million.

Full-year 2025 revenue was $236.3 million, up 15% from $204.7 million in 2024. FY2026 guidance is revenue of $270.0 million to $273.0 million, total revenue growth of 14% to 16%, adjusted EBITDA of approximately $25.0 million, free cash flow at breakeven and set deployment of approximately $10.0 million. As of September 30, 2026, cash, cash equivalents and short-term investments were $44.9 million, and debt was $98.4 million. The presentation also reports 95+ unique pediatric systems and sales in over 75 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.30%
Tags
current report
-
Rhea-AI Summary

OrthoPediatrics Corp. reported third-quarter 2026 revenue of $72.7 million, up 19% year over year, and raised full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million. Trauma and Deformity revenue rose 19% to $52.6 million, while Scoliosis revenue rose 18% to $19.2 million.

Gross profit was $54.0 million and gross margin was 74%, consistent with a year earlier. Net loss narrowed to $5.9 million, or $0.25 per basic and diluted share, from $11.8 million, or $0.50 per share. Adjusted EBITDA, a non-GAAP measure, was $6.9 million versus $6.2 million; free cash flow, also non-GAAP, was $1.6 million compared with $3.4 million used in the third quarter of 2025. The company recorded a $0.6 million impairment charge after determining the fair values of its ApiFix and MedTech trademark assets were below their carrying values.

For 2026, management reiterated expectations of approximately $10.0 million in annual set deployment, approximately $25.0 million in adjusted EBITDA, and breakeven free cash flow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.30%
Tags
current report
Rhea-AI Summary

OrthoPediatrics Corp. (KIDS) has received Amendment No. 4 to a Schedule 13D from Squadron Capital LLC, Squadron Capital Holdings LLC, Jennifer N. Pritzker, and David R. Pelizzon updating their ownership in the company. Squadron Capital LLC now directly holds 6,201,764 shares of common stock, representing 23.8% of the outstanding shares based on 26,109,788 shares outstanding as of August 4, 2026. Including direct and indirect holdings, Jennifer N. Pritzker may be deemed to beneficially own 6,216,471 shares (23.8%), and David R. Pelizzon 6,246,148 shares (23.9%).

The filing also reports that Squadron Capital LLC sold 22,500 shares on September 2, 2026 at a weighted average price of $23.35 and 302,369 shares on September 10, 2026 at a weighted average price of $21.01, in each case to provide additional capital for its other portfolio businesses, while retaining a significant stake in OrthoPediatrics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
ownership
-
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) had a major shareholder, Squadron Capital LLC, report the sale of 302,369 shares of common stock on September 10, 2026, at a weighted average price of $21.01 per share, in multiple trades between $21.00 and $21.69. After this sale, Squadron Capital LLC reported holding 6,201,764 shares directly. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses, and no Rule 10b5-1 trading plan is reported. Squadron Capital Holdings LLC is the controlling member of Squadron Capital LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
insider
-
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) reported that major shareholder Jennifer N. Pritzker, through Squadron Capital LLC, sold 302,369 shares of common stock on September 10, 2026 at a weighted average price of $21.01 per share, in multiple trades between $21.00 and $21.69. A separate line shows Pritzker holding 10,900 shares directly after the reported date. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses, and Pritzker expressly disclaims beneficial ownership of Squadron’s shares except to the extent of her pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
insider
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) reports that on September 10, 2026, 302,369 shares of common stock were sold in the open market by Squadron Capital LLC, an entity associated with director and ten percent owner David R. Pelizzon, at a weighted average price of $21.01 per share (range $21.00–$21.69). Following this sale, Squadron is reported with 6,201,764 indirectly held shares, while Pelizzon also holds 44,384 shares directly, including 17,959 restricted stock awards; he disclaims beneficial ownership of Squadron’s shares except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
insider
-
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) had a Form 4 filed for a large shareholder, Squadron Capital LLC, reporting a sale of 22,500 shares of Common Stock on September 2, 2026, at a weighted average price of $23.35 per share, in transactions ranging from $23.01 to $23.74. After this sale, Squadron Capital LLC reports holding 6,504,133 shares, which it holds directly, while Squadron Capital Holdings LLC is described as its controlling member. No Rule 10b5-1 trading plan is reported for this transaction, and a footnote states the sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
insider
-
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) reported that on September 2, 2026, an entity associated with 10% owner Jennifer N. Pritzker, Squadron Capital LLC, sold 22,500 shares of common stock in a sale reported as an open market or private transaction at a weighted average price of $23.35 per share, with individual trade prices ranging from $23.01 to $23.74. The filing states this sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses and that no Rule 10b5-1 trading plan is reported.

After the reported transaction, Jennifer N. Pritzker is shown as holding 10,900 shares directly, and additional shares are held indirectly through Squadron Capital LLC, the Tawani Foundation, the Pritzker Military Foundation, the reporting person's spouse, and the Pritzker Military Museum and Library. For each of these indirect positions, she may be deemed the beneficial owner but expressly disclaims beneficial ownership of the shares, except to the extent of her pecuniary interest in them.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
insider
Rhea-AI Summary

ORTHOPEDIATRICS CORP (KIDS) reported that director and ten percent owner David R. Pelizzon, through affiliated entity Squadron Capital LLC, indirectly sold 22,500 shares of common stock on September 2, 2026 at a weighted average price of $23.35 per share. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses. After this transaction, entities associated with Pelizzon held 6,504,133 indirect shares and he held 44,384 shares directly, including 17,959 restricted stock awards, while he expressly disclaims beneficial ownership of Squadron’s shares except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
insider

FAQ

How many ORTHOPEDIATRICS (KIDS) SEC filings are available on StockTitan?

StockTitan tracks 66 SEC filings for ORTHOPEDIATRICS (KIDS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ORTHOPEDIATRICS (KIDS)?

The most recent SEC filing for ORTHOPEDIATRICS (KIDS) was filed on October 28, 2026.